Interaction between Warfarin and Linezolid in Patients with Left Ventricular Assist System in Japan

Kinoshita, Sayoko; Wada, Keita; Matsuda, Sachi; Kuwahara, Taishi; Sunami, Hiroshi; Sato, Takuma; Seguchi, Osamu; Nakatani, Takeshi; Takada, Mitsutaka

doi:10.2169/internalmedicine.55.5756

Cited by 6 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DAP is also used to treat various bacterial infections caused by Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE) [16,17]. As mentioned above, LZD and DAP are also known to interact with WF, and therefore, pharmacists monitor the fluctuation of PT-INR carefully and provide prescription support [18].…”

Section: Antimicrobial Agentsmentioning

confidence: 99%

Role of the Transplant Pharmacist

Ikura¹,

Nakagita²,

Uno³

et al. 2022

Heart Transplantation - New Insights in Therapeutic Strategies

Self Cite

View full text Add to dashboard Cite

At the National Cerebral and Cardiovascular Center, Japan, pharmacists have been involved in drug treatment management and patient care as members of multidisciplinary heart transplant teams that include surgeons, physicians, recipient transplant coordinators, and nurses during the waiting period for heart transplantation (HTx), HTx surgery, and post-HTx. During the waiting period, pharmacists play an important role in adjusting the use of antibiotics, anticoagulants, and antiarrhythmics by patients receiving a ventricular assist device (VAD). During HTx surgery and post-HTx, pharmacists advise physicians regarding the individualized medication protocol for immunosuppression and infection prevention to be used for each patient based on the patient’s pre-HTx characteristics as well as gene polymorphisms. They thus contribute to reducing the burden on the physician through the sharing of tasks. Throughout all three phases of HTx, pharmacists repeatedly provide medication and adherence education to the patients and caregivers. It is hoped that an academic society-led training protocol as well as transplant pharmacists will be established in Japan and other developed countries, and that these specialized transplant pharmacists would then provide individualized pharmacotherapy for the use of various antibiotics, anticoagulants, and immunosuppressive agents that have a narrow range of treatment in VAD and HTx patients.

show abstract

Section: Antimicrobial Agentsmentioning

confidence: 99%

Role of the Transplant Pharmacist

Ikura¹,

Nakagita²,

Uno³

et al. 2022

Heart Transplantation - New Insights in Therapeutic Strategies

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is commonly used to treat pneumonia and skin and soft tissue infections caused by some gram‐positive bacteria, including methicillin‐resistant Staphylococcus aureus (MRSA) and vancomycin‐resistant enterococci (VRE). 5 , 6 Although LZD often shows good safety in clinical therapy, 7 the related adverse effects are frequent and occasionally severe. 8 A previous study showed that the risk of adverse effects increased with LZD exposure and duration of treatment, 5 and physicians should be more cautious when prescribing antimicrobials such as LZD due to the risk of drug–drug interactions (DDIs).…”

Section: Introductionmentioning

confidence: 99%

Clinical drug interactions between linezolid and other antibiotics: For adverse drug event monitoring

Shu,

Huo,

Yin

et al. 2024

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Detailed data on safety associated with drug–drug interactions (DDIs) between Linezolid (LZD) and other antibiotics are limited. The aim of this study was to investigate the safety signals related to these DDIs and to provide a reference for clinically related adverse drug event monitoring. Adverse event (AE) information from 1 January 2004 to 16 June 2022 of the target antibiotics including LZD using alone or in combination with LZD was extracted from the OpenVigil FDA data platform for safety signal analysis. The combined risk ratio model, reporting ratio method, Ω shrinkage measure model, and chi‐square statistics model were used to analyze the safety signals related to DDIs. Meanwhile, we evaluated the correlation and the influence of sex and age between the drug(s) and the target AE detected. There were 18991 AEs related to LZD. There were 2293, 1726, 4449, 821, 2431, 1053, and 463 AE reports when LZD was combined with amikacin, voriconazole, meropenem, clarithromycin, levofloxacin, piperacillin‐tazobactam, and azithromycin, respectively. Except for azithromycin, there were positive safety signals related to DDIs between LZD and these antibiotics. These DDIs might influence the incidence of 13, 16, 7, 7, 6, and 15 types of AEs, respectively, and is associated with higher reporting rates of AEs compared with use alone. Moreover, sex and age might influence the occurrence of AEs. We found that the combinations of LZD and other antibiotics are related to multiple AEs, such as hepatotoxicity, drug resistance and electrocardiogram QT prolonged, but further research is still required to investigate their underlying mechanisms. This study can provide a new reference for the safety monitoring of LZD combined with other antibiotics in clinical practice.

show abstract

Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD)

Nakagita

Wada

Mukai

et al. 2018

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Interaction between Warfarin and Linezolid in Patients with Left Ventricular Assist System in Japan

Abstract: These findings suggest that co-administration of linezolid results in increased PT-INR in patients with LVAS treated with warfarin.

Cited by 6 publications

References 24 publications

Role of the Transplant Pharmacist

Role of the Transplant Pharmacist

Clinical drug interactions between linezolid and other antibiotics: For adverse drug event monitoring

Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD)

Contact Info

Product

Resources

About